DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Conditions: Breast Cancer; Breast Cancer Female; Metastatic Triple-Negative Breast Carcinoma; ER Positive Breast Cancer; HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma; ER-negative Breast Cancer

Interventions: Drug: Datopotamab Deruxtecan

Sponsors: Sarah Sammons, MD; Daiichi Sankyo, Inc.

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 20, 2023Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments